APO Research
Talk to an analyst

APO RESEARCH · REPORT

High-Purity PLGA Polymers for Long-Acting Injectables

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global High-Purity PLGA Polymers for Long-Acting Injectables Market Outlook and Growth Opportunities 2026

13 August 2026198 pages

Choose your research edition.

Industry ResearchHigh-Purity PLGA Polymers for Long-Acting Injectables Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal High-Purity PLGA Polymers for Long-Acting Injectables Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal High-Purity PLGA Polymers for Long-Acting Injectables Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal High-Purity PLGA Polymers for Long-Acting Injectables Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal High-Purity PLGA Polymers for Long-Acting Injectables Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global High-Purity PLGA Polymers for Long-Acting Injectables market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for High-Purity PLGA Polymers for Long-Acting Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for High-Purity PLGA Polymers for Long-Acting Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for High-Purity PLGA Polymers for Long-Acting Injectables is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the High-Purity PLGA Polymers for Long-Acting Injectables market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the High-Purity PLGA Polymers for Long-Acting Injectables market include Evonik Industries AG, Corbion N.V., Ashland Inc., SEQENS, Mitsui Chemicals, Inc., Nanjing Well Pharmaceutical Group Co., Ltd., Guangzhou DiQi Pharmaceuticals Co., Ltd., Nomisma Healthcare Pvt. Ltd. and Zhejiang Langhua Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global High-Purity PLGA Polymers for Long-Acting Injectables market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of High-Purity PLGA Polymers for Long-Acting Injectables and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents High-Purity PLGA Polymers for Long-Acting Injectables sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the High-Purity PLGA Polymers for Long-Acting Injectables market size, projected growth trends, production technologies, key applications, and end-use industries.

High-Purity PLGA Polymers for Long-Acting Injectables Segment by Company

Evonik Industries AG

Corbion N.V.

Ashland Inc.

SEQENS

Mitsui Chemicals, Inc.

Nanjing Well Pharmaceutical Group Co., Ltd.

Guangzhou DiQi Pharmaceuticals Co., Ltd.

Nomisma Healthcare Pvt. Ltd.

Zhejiang Langhua Pharmaceutical Co., Ltd.

Hunan Er-Kang Pharmaceutical Co., Ltd.

Shanghai Libaimei Biotechnology Co., Ltd.

Zhejiang Bangyao Biomaterials Co., Ltd.

High-Purity PLGA Polymers for Long-Acting Injectables Segment by Type

PLGA 50:50

PLGA 75:25

PLGA 85:15

Other Ratios and Customized PLGA

High-Purity PLGA Polymers for Long-Acting Injectables Segment by Application

Sustained-release Microspheres

In-situ Forming Depot Systems

Biodegradable Drug-eluting Implants

Nanoparticle Drug Delivery Systems

Other Parenteral Controlled-release Applications

High-Purity PLGA Polymers for Long-Acting Injectables Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global High-Purity PLGA Polymers for Long-Acting Injectables status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions High-Purity PLGA Polymers for Long-Acting Injectables market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify High-Purity PLGA Polymers for Long-Acting Injectables significant trends, drivers, influence factors in global and regions.

6. To analyze High-Purity PLGA Polymers for Long-Acting Injectables competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High-Purity PLGA Polymers for Long-Acting Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of High-Purity PLGA Polymers for Long-Acting Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High-Purity PLGA Polymers for Long-Acting Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the High-Purity PLGA Polymers for Long-Acting Injectables market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global High-Purity PLGA Polymers for Long-Acting Injectables industry.

Chapter 3: Detailed analysis of High-Purity PLGA Polymers for Long-Acting Injectables manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of High-Purity PLGA Polymers for Long-Acting Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of High-Purity PLGA Polymers for Long-Acting Injectables in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. High-Purity PLGA Polymers for Long-Acting Injectables Industry Trends Table 2. High-Purity PLGA Polymers for Long-Acting Injectables Industry Drivers Table 3. High-Purity PLGA Polymers for Long-Acting Injectables Industry Opportunities and Challenges Table 4. High-Purity PLGA Polymers for Long-Acting Injectables Industry Restraints Table 5. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (US$ Million) & (2021-2026) Table 6. Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue Share by Company (2021-2026) Table 7. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Company (t) & (2021-2026) Table 8. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Company (2021-2026) Table 9. Global High-Purity PLGA Polymers for Long-Acting Injectables Average Price (USD/t) of Company (2021-2026) Table 10. Global High-Purity PLGA Polymers for Long-Acting Injectables Company Ranking, (2024-2026) & (USD Million) Table 11. Global High-Purity PLGA Polymers for Long-Acting Injectables Key Company Manufacturing Base & Headquarters Table 12. Global High-Purity PLGA Polymers for Long-Acting Injectables Company, Product Type & Application Table 13. Global High-Purity PLGA Polymers for Long-Acting Injectables Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global High-Purity PLGA Polymers for Long-Acting Injectables by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PLGA 50:50 Table 18. Significant Companies of PLGA 75:25 Table 19. Significant Companies of PLGA 85:15 Table 20. Significant Companies of Other Ratios and Customized PLGA Table 21. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type 2021 VS 2025 VS 2032 (t) Table 22. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type (2021-2026) & (t) Table 23. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type (2027-2032) & (t) Table 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Type (2021-2026) Table 25. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Type (2027-2032) Table 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type (2021-2026) Table 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Sustained-release Microspheres Table 32. Significant Companies of In-situ Forming Depot Systems Table 33. Significant Companies of Biodegradable Drug-eluting Implants Table 34. Significant Companies of Nanoparticle Drug Delivery Systems Table 35. Significant Companies of Other Parenteral Controlled-release Applications Table 36. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application 2021 VS 2025 VS 2032 (t) Table 37. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application (2021-2026) & (t) Table 38. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application (2027-2032) & (t) Table 39. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Application (2021-2026) Table 40. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Application (2027-2032) Table 41. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application (2021-2026) Table 45. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application (2027-2032) Table 46. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region: 2021 VS 2025 VS 2032 (t) Table 47. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2026) & (t) Table 48. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region (2021-2026) Table 49. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2027-2032) & (t) Table 50. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region (2027-2032) Table 51. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Region (2021-2026) Table 54. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Region (2027-2032) Table 56. Global High-Purity PLGA Polymers for Long-Acting Injectables Market Average Price (USD/t) by Region (2021-2026) Table 57. Global High-Purity PLGA Polymers for Long-Acting Injectables Market Average Price (USD/t) by Region (2027-2032) Table 58. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country: 2021 VS 2025 VS 2032 (t) Table 59. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026) & (t) Table 61. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2021-2026) Table 62. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2027-2032) & (t) Table 63. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Country (2027-2032) Table 64. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Market Share by Country (2021-2026) Table 66. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Market Share by Country (2027-2032) Table 68. Evonik Industries AG Company Information Table 69. Evonik Industries AG Business Overview Table 70. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 71. Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 72. Evonik Industries AG Recent Development Table 73. Corbion N.V. Company Information Table 74. Corbion N.V. Business Overview Table 75. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 76. Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 77. Corbion N.V. Recent Development Table 78. Ashland Inc. Company Information Table 79. Ashland Inc. Business Overview Table 80. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 81. Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 82. Ashland Inc. Recent Development Table 83. SEQENS Company Information Table 84. SEQENS Business Overview Table 85. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 86. SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 87. SEQENS Recent Development Table 88. Mitsui Chemicals, Inc. Company Information Table 89. Mitsui Chemicals, Inc. Business Overview Table 90. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 91. Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 92. Mitsui Chemicals, Inc. Recent Development Table 93. Nanjing Well Pharmaceutical Group Co., Ltd. Company Information Table 94. Nanjing Well Pharmaceutical Group Co., Ltd. Business Overview Table 95. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 96. Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 97. Nanjing Well Pharmaceutical Group Co., Ltd. Recent Development Table 98. Guangzhou DiQi Pharmaceuticals Co., Ltd. Company Information Table 99. Guangzhou DiQi Pharmaceuticals Co., Ltd. Business Overview Table 100. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 101. Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 102. Guangzhou DiQi Pharmaceuticals Co., Ltd. Recent Development Table 103. Nomisma Healthcare Pvt. Ltd. Company Information Table 104. Nomisma Healthcare Pvt. Ltd. Business Overview Table 105. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 106. Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 107. Nomisma Healthcare Pvt. Ltd. Recent Development Table 108. Zhejiang Langhua Pharmaceutical Co., Ltd. Company Information Table 109. Zhejiang Langhua Pharmaceutical Co., Ltd. Business Overview Table 110. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 111. Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 112. Zhejiang Langhua Pharmaceutical Co., Ltd. Recent Development Table 113. Hunan Er-Kang Pharmaceutical Co., Ltd. Company Information Table 114. Hunan Er-Kang Pharmaceutical Co., Ltd. Business Overview Table 115. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 116. Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 117. Hunan Er-Kang Pharmaceutical Co., Ltd. Recent Development Table 118. Shanghai Libaimei Biotechnology Co., Ltd. Company Information Table 119. Shanghai Libaimei Biotechnology Co., Ltd. Business Overview Table 120. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 121. Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 122. Shanghai Libaimei Biotechnology Co., Ltd. Recent Development Table 123. Zhejiang Bangyao Biomaterials Co., Ltd. Company Information Table 124. Zhejiang Bangyao Biomaterials Co., Ltd. Business Overview Table 125. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales (t), Value (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 126. Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio Table 127. Zhejiang Bangyao Biomaterials Co., Ltd. Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. High-Purity PLGA Polymers for Long-Acting Injectables Distributors List Table 131. High-Purity PLGA Polymers for Long-Acting Injectables Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. High-Purity PLGA Polymers for Long-Acting Injectables Product Image Figure 2. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 4. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales (2021-2032) & (t) Figure 5. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Average Price (USD/t) & (2021-2032) Figure 6. Global High-Purity PLGA Polymers for Long-Acting Injectables Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PLGA 50:50 Image Figure 10. PLGA 75:25 Image Figure 11. PLGA 85:15 Image Figure 12. Other Ratios and Customized PLGA Image Figure 13. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type (2021 VS 2025 VS 2032) & (t) Figure 14. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Type (2021-2032) Figure 16. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type (2021-2032) Figure 19. Sustained-release Microspheres Image Figure 20. In-situ Forming Depot Systems Image Figure 21. Biodegradable Drug-eluting Implants Image Figure 22. Nanoparticle Drug Delivery Systems Image Figure 23. Other Parenteral Controlled-release Applications Image Figure 24. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application (2021 VS 2025 VS 2032) & (t) Figure 25. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Application (2021-2032) Figure 27. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application (2021-2032) Figure 30. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region: 2021 VS 2025 VS 2032 (t) Figure 31. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 35. North America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 37. Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 41. South America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. High-Purity PLGA Polymers for Long-Acting Injectables Value Chain Figure 129. Manufacturing Cost Structure Figure 130. High-Purity PLGA Polymers for Long-Acting Injectables Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • PLGA 50:50
  • PLGA 75:25
  • PLGA 85:15
  • Other Ratios and Customized PLGA
Applications
  • Sustained-release Microspheres
  • In-situ Forming Depot Systems
  • Biodegradable Drug-eluting Implants
  • Nanoparticle Drug Delivery Systems
  • Other Parenteral Controlled-release Applications
Companies covered
  • Evonik Industries AG
  • Corbion N.V.
  • Ashland Inc.
  • SEQENS
  • Mitsui Chemicals, Inc.
  • Nanjing Well Pharmaceutical Group Co., Ltd.
  • Guangzhou DiQi Pharmaceuticals Co., Ltd.
  • Nomisma Healthcare Pvt. Ltd.
  • Zhejiang Langhua Pharmaceutical Co., Ltd.
  • Hunan Er-Kang Pharmaceutical Co., Ltd.
  • Shanghai Libaimei Biotechnology Co., Ltd.
  • Zhejiang Bangyao Biomaterials Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  4. 1.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume (2021-2032)
  5. 1.2.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 High-Purity PLGA Polymers for Long-Acting Injectables Market Dynamics
  1. 2.1 High-Purity PLGA Polymers for Long-Acting Injectables Industry Trends
  2. 2.2 High-Purity PLGA Polymers for Long-Acting Injectables Industry Drivers
  3. 2.3 High-Purity PLGA Polymers for Long-Acting Injectables Industry Opportunities and Challenges
  4. 2.4 High-Purity PLGA Polymers for Long-Acting Injectables Industry Restraints
3 High-Purity PLGA Polymers for Long-Acting Injectables Market by Company
  1. 3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Company Revenue Ranking in 2025
  2. 3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Revenue by Company (2021-2026)
  3. 3.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Company (2021-2026)
  4. 3.4 Global High-Purity PLGA Polymers for Long-Acting Injectables Average Price by Company (2021-2026)
  5. 3.5 Global High-Purity PLGA Polymers for Long-Acting Injectables Company Ranking (2024-2026)
  6. 3.6 Global High-Purity PLGA Polymers for Long-Acting Injectables Company Manufacturing Base and Headquarters
  7. 3.7 Global High-Purity PLGA Polymers for Long-Acting Injectables Company Product Type and Application
  8. 3.8 Global High-Purity PLGA Polymers for Long-Acting Injectables Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 High-Purity PLGA Polymers for Long-Acting Injectables Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 High-Purity PLGA Polymers for Long-Acting Injectables Market by Type
  1. 4.1 High-Purity PLGA Polymers for Long-Acting Injectables Type Introduction
  2. 4.1.1 PLGA 50:50
  3. 4.1.2 PLGA 75:25
  4. 4.1.3 PLGA 85:15
  5. 4.1.4 Other Ratios and Customized PLGA
  6. 4.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type
  7. 4.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Type (2021-2032)
  9. 4.2.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Type (2021-2032)
  10. 4.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type
  11. 4.3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Type (2021-2032)
  13. 4.3.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type (2021-2032)
5 High-Purity PLGA Polymers for Long-Acting Injectables Market by Application
  1. 5.1 High-Purity PLGA Polymers for Long-Acting Injectables Application Introduction
  2. 5.1.1 Sustained-release Microspheres
  3. 5.1.2 In-situ Forming Depot Systems
  4. 5.1.3 Biodegradable Drug-eluting Implants
  5. 5.1.4 Nanoparticle Drug Delivery Systems
  6. 5.1.5 Other Parenteral Controlled-release Applications
  7. 5.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application
  8. 5.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume by Application (2021-2032)
  10. 5.2.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Volume Share by Application (2021-2032)
  11. 5.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application
  12. 5.3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Application (2021-2032)
  14. 5.3.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application (2021-2032)
6 High-Purity PLGA Polymers for Long-Acting Injectables Regional Sales and Value Analysis
  1. 6.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2021-2032)
  3. 6.2.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region: 2021-2026
  4. 6.2.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Region (2027-2032)
  5. 6.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region (2021-2032)
  7. 6.4.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region: 2021-2026
  8. 6.4.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Region (2027-2032)
  9. 6.5 Global High-Purity PLGA Polymers for Long-Acting Injectables Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  12. 6.6.2 North America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  15. 6.7.2 Europe High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  21. 6.9.2 South America High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Country, 2025 VS 2032
7 High-Purity PLGA Polymers for Long-Acting Injectables Country-level Sales and Value Analysis
  1. 7.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2032)
  4. 7.3.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2021-2026)
  5. 7.3.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales by Country (2027-2032)
  6. 7.4 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country (2021-2032)
  7. 7.4.1 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country (2021-2026)
  8. 7.4.2 Global High-Purity PLGA Polymers for Long-Acting Injectables Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt High-Purity PLGA Polymers for Long-Acting Injectables Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Evonik Industries AG
  2. 8.1.1 Evonik Industries AG Company Information
  3. 8.1.2 Evonik Industries AG Business Overview
  4. 8.1.3 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Evonik Industries AG High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  6. 8.1.5 Evonik Industries AG Recent Developments
  7. 8.2 Corbion N.V.
  8. 8.2.1 Corbion N.V. Company Information
  9. 8.2.2 Corbion N.V. Business Overview
  10. 8.2.3 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Corbion N.V. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  12. 8.2.5 Corbion N.V. Recent Developments
  13. 8.3 Ashland Inc.
  14. 8.3.1 Ashland Inc. Company Information
  15. 8.3.2 Ashland Inc. Business Overview
  16. 8.3.3 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ashland Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  18. 8.3.5 Ashland Inc. Recent Developments
  19. 8.4 SEQENS
  20. 8.4.1 SEQENS Company Information
  21. 8.4.2 SEQENS Business Overview
  22. 8.4.3 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 SEQENS High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  24. 8.4.5 SEQENS Recent Developments
  25. 8.5 Mitsui Chemicals, Inc.
  26. 8.5.1 Mitsui Chemicals, Inc. Company Information
  27. 8.5.2 Mitsui Chemicals, Inc. Business Overview
  28. 8.5.3 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Mitsui Chemicals, Inc. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  30. 8.5.5 Mitsui Chemicals, Inc. Recent Developments
  31. 8.6 Nanjing Well Pharmaceutical Group Co., Ltd.
  32. 8.6.1 Nanjing Well Pharmaceutical Group Co., Ltd. Company Information
  33. 8.6.2 Nanjing Well Pharmaceutical Group Co., Ltd. Business Overview
  34. 8.6.3 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Nanjing Well Pharmaceutical Group Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  36. 8.6.5 Nanjing Well Pharmaceutical Group Co., Ltd. Recent Developments
  37. 8.7 Guangzhou DiQi Pharmaceuticals Co., Ltd.
  38. 8.7.1 Guangzhou DiQi Pharmaceuticals Co., Ltd. Company Information
  39. 8.7.2 Guangzhou DiQi Pharmaceuticals Co., Ltd. Business Overview
  40. 8.7.3 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Guangzhou DiQi Pharmaceuticals Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  42. 8.7.5 Guangzhou DiQi Pharmaceuticals Co., Ltd. Recent Developments
  43. 8.8 Nomisma Healthcare Pvt. Ltd.
  44. 8.8.1 Nomisma Healthcare Pvt. Ltd. Company Information
  45. 8.8.2 Nomisma Healthcare Pvt. Ltd. Business Overview
  46. 8.8.3 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Nomisma Healthcare Pvt. Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  48. 8.8.5 Nomisma Healthcare Pvt. Ltd. Recent Developments
  49. 8.9 Zhejiang Langhua Pharmaceutical Co., Ltd.
  50. 8.9.1 Zhejiang Langhua Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Zhejiang Langhua Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Zhejiang Langhua Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  54. 8.9.5 Zhejiang Langhua Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Hunan Er-Kang Pharmaceutical Co., Ltd.
  56. 8.10.1 Hunan Er-Kang Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Hunan Er-Kang Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hunan Er-Kang Pharmaceutical Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  60. 8.10.5 Hunan Er-Kang Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Shanghai Libaimei Biotechnology Co., Ltd.
  62. 8.11.1 Shanghai Libaimei Biotechnology Co., Ltd. Company Information
  63. 8.11.2 Shanghai Libaimei Biotechnology Co., Ltd. Business Overview
  64. 8.11.3 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Shanghai Libaimei Biotechnology Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  66. 8.11.5 Shanghai Libaimei Biotechnology Co., Ltd. Recent Developments
  67. 8.12 Zhejiang Bangyao Biomaterials Co., Ltd.
  68. 8.12.1 Zhejiang Bangyao Biomaterials Co., Ltd. Company Information
  69. 8.12.2 Zhejiang Bangyao Biomaterials Co., Ltd. Business Overview
  70. 8.12.3 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Zhejiang Bangyao Biomaterials Co., Ltd. High-Purity PLGA Polymers for Long-Acting Injectables Product Portfolio
  72. 8.12.5 Zhejiang Bangyao Biomaterials Co., Ltd. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 High-Purity PLGA Polymers for Long-Acting Injectables Value Chain Analysis
  2. 9.1.1 High-Purity PLGA Polymers for Long-Acting Injectables Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 High-Purity PLGA Polymers for Long-Acting Injectables Sales Mode & Process
  6. 9.2 High-Purity PLGA Polymers for Long-Acting Injectables Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 High-Purity PLGA Polymers for Long-Acting Injectables Distributors
  9. 9.2.3 High-Purity PLGA Polymers for Long-Acting Injectables Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst